Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viramidine Lead-in vs Standard Dosing in Chronic Hepatitis C
NCT00305383Phase 2Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Nov 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of taribavirin in hepatitis C (HCV) (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Rapid Virologic Response at 4 weeks and Adverse Events. Started Nov 2005; status: terminated.
02
Drugs
taribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00305383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305383.